Banks - Regional
Build Your Comparison
Side-by-side financial analysisStock Comparison
ECBK vs CARE
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
ECBK vs CARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Banks - Regional | Banks - Regional |
| Market Cap | $178M | $686M |
| Revenue (TTM) | $80M | $252M |
| Net Income (TTM) | $8M | $31M |
| Gross Margin | 39.9% | 61.2% |
| Operating Margin | 13.1% | 15.9% |
| Forward P/E | 21.6x | 5.7x |
| Total Debt | $285M | $179M |
| Cash & Equiv. | $95M | $105M |
ECBK vs CARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 22 | Jun 26 | Return |
|---|---|---|---|
| ECB Bancorp, Inc. (ECBK) | 100 | 145.3 | +45.3% |
| Carter Bankshares, … (CARE) | 100 | 221.9 | +121.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ECBK vs CARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ECBK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.44
- Rev growth 16.5%, EPS growth 95.8%
- Lower volatility, beta 0.44, current ratio 0.10x
CARE is the clearest fit if your priority is long-term compounding and bank quality.
- 150.2% 10Y total return vs ECBK's 44.1%
- NIM 2.7% vs ECBK's 2.0%
- +86.8% vs ECBK's +34.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.5% NII/revenue growth vs CARE's 6.2% | |
| Value | Better valuation composite | |
| Quality / Margins | Efficiency ratio 0.3% vs CARE's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.44 vs CARE's 0.50 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +86.8% vs ECBK's +34.3% | |
| Efficiency (ROA) | Efficiency ratio 0.3% vs CARE's 0.5% |
ECBK vs CARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ECBK vs CARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CARE leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CARE is the larger business by revenue, generating $252M annually — 3.2x ECBK's $80M. Profitability is closely matched — net margins range from 12.5% (CARE) to 9.8% (ECBK).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $80M | $252M |
| EBITDAEarnings before interest/tax | $11M | $46M |
| Net IncomeAfter-tax profit | $8M | $31M |
| Free Cash FlowCash after capex | $9M | $30M |
| Gross MarginGross profit ÷ Revenue | +39.9% | +61.2% |
| Operating MarginEBIT ÷ Revenue | +13.1% | +15.9% |
| Net MarginNet income ÷ Revenue | +9.8% | +12.5% |
| FCF MarginFCF ÷ Revenue | +11.3% | +11.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +82.4% | +8.3% |
Valuation Metrics
ECBK leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, ECBK trades at a 2% valuation discount to CARE's 22.1x P/E. On an enterprise value basis, CARE's 19.0x EV/EBITDA is more attractive than ECBK's 35.5x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $178M | $686M |
| Enterprise ValueMkt cap + debt − cash | $368M | $759M |
| Trailing P/EPrice ÷ TTM EPS | 21.61x | 22.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.67x |
| PEG RatioP/E ÷ EPS growth rate | 1.16x | — |
| EV / EBITDAEnterprise value multiple | 35.47x | 18.98x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 2.69x |
| Price / BookPrice ÷ Book value/share | 0.98x | 1.66x |
| Price / FCFMarket cap ÷ FCF | 19.80x | 21.57x |
Profitability & Efficiency
CARE leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
CARE delivers a 7.6% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $5 for ECBK. CARE carries lower financial leverage with a 0.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to ECBK's 1.66x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs ECBK's 7/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +4.6% | +7.6% |
| ROA (TTM)Return on assets | +0.5% | +0.7% |
| ROICReturn on invested capital | +1.8% | +5.7% |
| ROCEReturn on capital employed | +2.3% | +1.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 |
| Debt / EquityFinancial leverage | 1.66x | 0.43x |
| Net DebtTotal debt minus cash | $190M | $73M |
| Cash & Equiv.Liquid assets | $95M | $105M |
| Total DebtShort + long-term debt | $285M | $179M |
| Interest CoverageEBIT ÷ Interest expense | 0.22x | 0.39x |
Total Returns (Dividends Reinvested)
CARE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $23,985 today (with dividends reinvested), compared to $14,414 for ECBK. Over the past 12 months, CARE leads with a +86.8% total return vs ECBK's +34.3%. The 3-year compound annual growth rate (CAGR) favors CARE at 26.8% vs ECBK's 15.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +17.3% | +59.9% |
| 1-Year ReturnPast 12 months | +34.3% | +86.8% |
| 3-Year ReturnCumulative with dividends | +55.6% | +103.8% |
| 5-Year ReturnCumulative with dividends | +44.1% | +139.8% |
| 10-Year ReturnCumulative with dividends | +44.1% | +150.2% |
| CAGR (3Y)Annualised 3-year return | +15.9% | +26.8% |
Risk & Volatility
ECBK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ECBK is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than CARE's 0.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.45x | 0.50x |
| 52-Week HighHighest price in past year | $20.50 | $31.40 |
| 52-Week LowLowest price in past year | $14.82 | $16.27 |
| % of 52W HighCurrent price vs 52-week peak | +99.1% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 59.4 | 76.8 |
| Avg Volume (50D)Average daily shares traded | 11K | 323K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $28.50 |
| # AnalystsCovering analysts | — | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.6% | +2.9% |
CARE leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ECBK leads in 2 (Valuation Metrics, Risk & Volatility).
ECBK vs CARE: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ECBK or CARE a better buy right now?
For growth investors, ECB Bancorp, Inc.
(ECBK) is the stronger pick with 16. 5% revenue growth year-over-year, versus 6. 2% for Carter Bankshares, Inc. (CARE). ECB Bancorp, Inc. (ECBK) offers the better valuation at 21. 6x trailing P/E, making it the more compelling value choice. Analysts rate Carter Bankshares, Inc. (CARE) a "Hold" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ECBK or CARE?
On trailing P/E, ECB Bancorp, Inc.
(ECBK) is the cheapest at 21. 6x versus Carter Bankshares, Inc. at 22. 1x.
03Which is the better long-term investment — ECBK or CARE?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +139. 8%, compared to +44. 1% for ECB Bancorp, Inc. (ECBK). Over 10 years, the gap is even starker: CARE returned +150. 2% versus ECBK's +44. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ECBK or CARE?
By beta (market sensitivity over 5 years), ECB Bancorp, Inc.
(ECBK) is the lower-risk stock at 0. 45β versus Carter Bankshares, Inc. 's 0. 50β — meaning CARE is approximately 12% more volatile than ECBK relative to the S&P 500. On balance sheet safety, Carter Bankshares, Inc. (CARE) carries a lower debt/equity ratio of 43% versus 166% for ECB Bancorp, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ECBK or CARE?
By revenue growth (latest reported year), ECB Bancorp, Inc.
(ECBK) is pulling ahead at 16. 5% versus 6. 2% for Carter Bankshares, Inc. (CARE). On earnings-per-share growth, the picture is similar: ECB Bancorp, Inc. grew EPS 95. 8% year-over-year, compared to 32. 1% for Carter Bankshares, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ECBK or CARE?
Carter Bankshares, Inc.
(CARE) is the more profitable company, earning 12. 3% net margin versus 9. 8% for ECB Bancorp, Inc. — meaning it keeps 12. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CARE leads at 15. 7% versus 13. 1% for ECBK. At the gross margin level — before operating expenses — CARE leads at 61. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — ECBK or CARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ECBK or CARE better for a retirement portfolio?
For long-horizon retirement investors, Carter Bankshares, Inc.
(CARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50), +150. 2% 10Y return). Both have compounded well over 10 years (CARE: +150. 2%, ECBK: +44. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ECBK and CARE?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ECBK is a small-cap high-growth stock; CARE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.